FDA Proposes Withdrawing Makena ' s Approval FDA Proposes Withdrawing Makena ' s Approval

A postmarketing study for the drug, which is supposed to reduce the risk of preterm birth, failed to substantiate any clinical benefit or effect on gestational age at delivery, the agency said.News Alerts
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Ob/Gyn & Women ' s Health News Alert Source Type: news